当前位置: X-MOL 学术Allergy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Challenge of De‐labeling Penicillin Allergy
Allergy ( IF 12.6 ) Pub Date : 2019-05-26 , DOI: 10.1111/all.13848
Cosby A Stone 1 , Jason Trubiano 2, 3, 4, 5 , David T Coleman 1 , Christine R F Rukasin 1 , Elizabeth J Phillips 6, 7, 8, 9
Affiliation  

Even though 8%‐25% of most populations studied globally are labeled as penicillin allergic, most diagnoses of penicillin allergy are made in childhood and relate to events that are either not allergic in nature, are low risk for immediate hypersensitivity, or are a potential true allergy that has waned over time. Penicillin allergy labels directly impact antimicrobial stewardship by leading to use of less effective and broader spectrum antimicrobials and are associated with antimicrobial resistance. They may also delay appropriate antimicrobial therapy and lead to increased risk of specific adverse healthcare outcomes. Operationalizing penicillin allergy de‐labeling into a new arm of antimicrobial stewardship programs (ASPs) has become an increasing global focus.

中文翻译:

去标签青霉素过敏的挑战

尽管全球研究的大多数人群中有 8%-25% 被标记为对青霉素过敏,但大多数青霉素过敏诊断是在儿童时期做出的,并且与本质上不过敏、立即过敏风险低或潜在的事件有关真正的过敏随着时间的推移而减弱。青霉素过敏标签通过导致使用效果较差和广谱的抗菌剂直接影响抗菌素管理,并与抗菌素耐药性有关。它们还可能延迟适当的抗菌治疗,并导致特定不良医疗保健结果的风险增加。将青霉素过敏去标签化为抗菌药物管理计划 (ASP) 的一个新分支已成为全球日益关注的焦点。
更新日期:2019-05-26
down
wechat
bug